- NexgenRx (TSXV:NXG) ended Q3 2025 with a flourish, posting strong revenue and EBITDA growth
- NexgenRx is the only independent full-service third-party administrator and technology solutions provider in Canada, granting it a differentiated position in the healthcare and dental claims marketplace
- The market-beating stock has added 36.67 per cent year-over-year and 95.24 per cent since 2020, comfortably ahead of the TSX’s 17.79 per cent and 75.72 per cent efforts, respectively
NexgenRx (TSXV:NXG), a micro-cap admin and tech solutions company, ended Q3 2025 with a flourish, posting strong revenue and EBITDA growth. Here are the highlights:
- Revenue reached C$4,616,066, up by 13.43 per cent year-over-year (YoY), driven by organic growth and an expanding service suite.
- Operating expenses of C$243,421, up by 8 per cent YoY, because of IT implementation expenses, consulting services and compensation adjustments.
- EBITDA came to C$887,671, up by C$441,224 YoY, with the year-to-date figure standing at C$2,343,703, showing management’s emphasis on cost controls.
- Net income grew by C$440,550 YoY, up from C$150,000, and rose from C$350,000 in Q2 2025.
- Dividends paid in August and September amounted to C$355,586 in common share dividends and C$33,000 in preferred share dividends.
- Cash totaled C$2,541,906 as of September 30, 2025.
The company has managed to grow revenue annually from C$10.57 million in 2020 to C$16.48 million in 2024, and is on track for a new record in 2025.
Concurrently, overall net income has been positive over the period to date, proving NexgenRX’s ability to parlay its leadership position into profitable growth.
Management commentary
“Our Q3 results reflect our continued pattern of increasing revenues and EBITDA on a quarter-by-quarter basis over the past several years,” Ron Loucks, president and chief executive officer of NexgenRX, said in Thursday’s news release. “This continued growth cycle has positioned the company to continue to generate free cash flow, supported by our strong recurring revenues and sales pipelines.”
About NexgenRx
NexgenRx is the only independent full-service third-party administrator and technology solutions provider in Canada. The company’s SaaS offerings, geared towards drug, dental and other healthcare plan providers, include proprietary full front-end, eligibility, enrolment, hour bank and mobile access capabilities, as well as claims adjudication and full network coverage.
NexgenRx stock (TSXV:NXG) last traded at C$0.41. The stock has added 36.67 per cent year-over-year and 95.24 per cent since 2020, comfortably ahead of the TSX’s 17.79 per cent and 75.72 per cent efforts, respectively.
Join the discussion: Find out what investors are saying about this market-beating stock on the NexgenRX Inc. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
For full disclaimer information, please click here.
